Literature DB >> 15230212

[The impact of comprehensive cardiac rehabilitation in patients up to 55 years old after acute myocardial infarction treated with primary coronary intervention].

Katarzyna Piestrzeniewicz1, Natalia Navarro-Kuczborska, Halina Bolińska, Anna Jegier, Marek Maciejewski.   

Abstract

UNLABELLED: The aim of our study was to evaluate the impact of comprehensive 3-phases cardiac rehabilitation in patients aged up to 55 years after acute myocardial infarction treated with primary coronary intervention (PCI) of the infarction related artery on the cardiovascular status, modification of coronary risk factors, psychological and physical status and exercise tolerance.
METHODS: Out of 106 consecutive patients aged up to 55 years with acute myocardial infarction (AMI) with ST-segment elevation, treated with primary coronary intervention (PCI) of the infarction related artery 71 patients entered the study and were randomized either to the Study Group (GB) or to the Control Group (GK). 31 patients of GB underwent 3-phases cardiac rehabilitation program and 40 patients of GK did not participate in phase III of the program. At phase I of the rehabilitation and 6 months after myocardial infarction physical examination, echocardiography and treadmill exercise test were performed.
RESULTS: At 6-months follow-up chest pain and symptoms of heart failure were significantly less common (p < 0.001) and a tendency for fewer new cardiac events and re-PCI was noted in GB. Self-evaluated, significantly greater improvement in the emotional and physical status as well as in physical activity (p < 0.001) was achieved in GB. In GB better exercise tolerance on treadmill exercise test, greater improvement in left ventricular ejection fraction (p < 0.05) and contractile index (p < 0.05) on echocardiography were observed. The effects of the secondary prevention in terms of smoking cessation and obesity were not satisfactory in both groups.
CONCLUSION: 3-phases comprehensive cardiac rehabilitation in patients with AMI treated with PCI of the infarction related artery improves recovery at 6-month follow-up. It has a favorable impact on the anginal and heart failure symptoms, cardiac risk factors (especially physical activity, restrictive diet), psychological and physical status. It contributes towards maintaining a further event-free period. It improves selected cardiovascular parameters such as exercise tolerance, segmental and global left ventricular function.

Entities:  

Mesh:

Year:  2004        PMID: 15230212

Source DB:  PubMed          Journal:  Pol Arch Med Wewn


  5 in total

Review 1.  Exercise-based cardiac rehabilitation for coronary heart disease.

Authors:  Balraj S Heran; Jenny Mh Chen; Shah Ebrahim; Tiffany Moxham; Neil Oldridge; Karen Rees; David R Thompson; Rod S Taylor
Journal:  Cochrane Database Syst Rev       Date:  2011-07-06

Review 2.  Exercise-based cardiac rehabilitation for coronary heart disease.

Authors:  Grace Dibben; James Faulkner; Neil Oldridge; Karen Rees; David R Thompson; Ann-Dorthe Zwisler; Rod S Taylor
Journal:  Cochrane Database Syst Rev       Date:  2021-11-06

Review 3.  Exercise-based cardiac rehabilitation for coronary heart disease.

Authors:  Lindsey Anderson; David R Thompson; Neil Oldridge; Ann-Dorthe Zwisler; Karen Rees; Nicole Martin; Rod S Taylor
Journal:  Cochrane Database Syst Rev       Date:  2016-01-05

4.  A hybrid cardiac rehabilitation is as effective as a hospital-based program in reducing chest pain intensity and discomfort.

Authors:  Mozhgan Saeidi; Ali Soroush; Saeid Komasi; Puneetpal Singh
Journal:  Korean J Pain       Date:  2017-09-29

5.  OPTImal CArdiac REhabilitation (OPTICARE) following Acute Coronary Syndromes: Rationale and design of a randomised, controlled trial to investigate the benefits of expanded educational and behavioural intervention programs.

Authors:  M Sunamura; N Ter Hoeve; H J G van den Berg-Emons; M Haverkamp; K Redekop; M L Geleijnse; H J Stam; E Boersma; R T van Domburg
Journal:  Neth Heart J       Date:  2013-07       Impact factor: 2.380

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.